Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy
The efficacy of intravesical onabotulinumtoxinA (BTXA) in the treatment of overactive bladder (OAB) has been well documented. The use of BTXA injection in orthotopic neobladders is yet to be studied. We present 4 cases of patients injected with intravesical BTXA for overactive orthotopic ileal neobl...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Continence Society
2016-03-01
|
| Series: | International Neurourology Journal |
| Subjects: | |
| Online Access: | http://www.einj.org/upload/pdf/inj-1630380-190.pdf |
| _version_ | 1828961459918340096 |
|---|---|
| author | Nathan Hoag Vincent Tse Audrey Wang Eric Chung Johan Gani |
| author_facet | Nathan Hoag Vincent Tse Audrey Wang Eric Chung Johan Gani |
| author_sort | Nathan Hoag |
| collection | DOAJ |
| description | The efficacy of intravesical onabotulinumtoxinA (BTXA) in the treatment of overactive bladder (OAB) has been well documented. The use of BTXA injection in orthotopic neobladders is yet to be studied. We present 4 cases of patients injected with intravesical BTXA for overactive orthotopic ileal neobladder. We recorded patient demographics, presenting and follow-up symptoms, urodynamic profiles, and Patient Global Impression of Improvement (PGI-I) scores. The 4 patients reported varying degrees of subjective improvements in the symptoms, including urgency, urge incontinence, and pad usage. Mean follow-up duration was 8.3 months (range, 5–14 months). Average PGI-I score was 3 (“a little better”) (range, 2–4). To our knowledge, the current study is the first case series examining BTXA injection for orthotopic neobladder overactivity. BTXA injection yielded varying degrees of objective and subjective improvements, without significant complications. Intravesical BTXA injection is feasible and may be considered as a potential treatment alternative for OAB in orthotopic neobladders, although further study is warranted. |
| first_indexed | 2024-12-14T09:45:20Z |
| format | Article |
| id | doaj.art-bc77eac747704ad8a64c0570d1542427 |
| institution | Directory Open Access Journal |
| issn | 2093-4777 2093-6931 |
| language | English |
| last_indexed | 2024-12-14T09:45:20Z |
| publishDate | 2016-03-01 |
| publisher | Korean Continence Society |
| record_format | Article |
| series | International Neurourology Journal |
| spelling | doaj.art-bc77eac747704ad8a64c0570d15424272022-12-21T23:07:39ZengKorean Continence SocietyInternational Neurourology Journal2093-47772093-69312016-03-01201818510.5213/inj.1630380.190561Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and EfficacyNathan Hoag0Vincent Tse1Audrey Wang2Eric Chung3Johan Gani4 Department of Urology, Austin Hospital, University of Melbourne, Melbourne, Australia Department of Urology, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia Department of Urology, Westmead Hospital, Macquarie University, Sydney, Australia Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia Department of Urology, Austin Hospital, University of Melbourne, Melbourne, AustraliaThe efficacy of intravesical onabotulinumtoxinA (BTXA) in the treatment of overactive bladder (OAB) has been well documented. The use of BTXA injection in orthotopic neobladders is yet to be studied. We present 4 cases of patients injected with intravesical BTXA for overactive orthotopic ileal neobladder. We recorded patient demographics, presenting and follow-up symptoms, urodynamic profiles, and Patient Global Impression of Improvement (PGI-I) scores. The 4 patients reported varying degrees of subjective improvements in the symptoms, including urgency, urge incontinence, and pad usage. Mean follow-up duration was 8.3 months (range, 5–14 months). Average PGI-I score was 3 (“a little better”) (range, 2–4). To our knowledge, the current study is the first case series examining BTXA injection for orthotopic neobladder overactivity. BTXA injection yielded varying degrees of objective and subjective improvements, without significant complications. Intravesical BTXA injection is feasible and may be considered as a potential treatment alternative for OAB in orthotopic neobladders, although further study is warranted.http://www.einj.org/upload/pdf/inj-1630380-190.pdfAdministration, IntravesicalOnabotulinumtoxinAUrinary Reservoirs, ContinentUrinary Bladder, OveractiveUrinary Diversion |
| spellingShingle | Nathan Hoag Vincent Tse Audrey Wang Eric Chung Johan Gani Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy International Neurourology Journal Administration, Intravesical OnabotulinumtoxinA Urinary Reservoirs, Continent Urinary Bladder, Overactive Urinary Diversion |
| title | Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy |
| title_full | Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy |
| title_fullStr | Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy |
| title_full_unstemmed | Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy |
| title_short | Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy |
| title_sort | intravesical onabotulinumtoxina injection for overactive orthotopic ileal neobladder feasibility and efficacy |
| topic | Administration, Intravesical OnabotulinumtoxinA Urinary Reservoirs, Continent Urinary Bladder, Overactive Urinary Diversion |
| url | http://www.einj.org/upload/pdf/inj-1630380-190.pdf |
| work_keys_str_mv | AT nathanhoag intravesicalonabotulinumtoxinainjectionforoveractiveorthotopicilealneobladderfeasibilityandefficacy AT vincenttse intravesicalonabotulinumtoxinainjectionforoveractiveorthotopicilealneobladderfeasibilityandefficacy AT audreywang intravesicalonabotulinumtoxinainjectionforoveractiveorthotopicilealneobladderfeasibilityandefficacy AT ericchung intravesicalonabotulinumtoxinainjectionforoveractiveorthotopicilealneobladderfeasibilityandefficacy AT johangani intravesicalonabotulinumtoxinainjectionforoveractiveorthotopicilealneobladderfeasibilityandefficacy |